18F-FDG uptake on PET is a predictive marker of thymidylate synthase expression in patients with thoracic neoplasms

Kaira,Kyoichi; Yamamoto,Nobuyuki; Endo,Masahiro; Kenmotsu,Hirotsugu; Naito,Tateaki; Ono,Akira; Murakami,Haruyasu; Ohde,Yasuhisa; Nakajima,Takashi; Takahashi,Toshiaki

doi:10.3892/or.2013.2816

18F-FDG uptake on PET is a predictive marker of thymidylate synthase expression in patients with thoracic neoplasms

Authors:
- Kyoichi Kaira
- Nobuyuki Yamamoto
- Masahiro Endo
- Hirotsugu Kenmotsu
- Tateaki Naito
- Akira Ono
- Haruyasu Murakami
- Yasuhisa Ohde
- Takashi Nakajima
- Toshiaki Takahashi
View Affiliations

Affiliations: Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan, Division of Diagnostic Radiology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan, Division of Thoracic Surgery, Shizuoka Cancer Center, Shizuoka 411-8777, Japan, Division of Pathology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan
Published online on: October 24, 2013 https://doi.org/10.3892/or.2013.2816
Pages: 209-215

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of this study was to investigate the relationship between the expression levels of thymidylate synthase (TS) and 2-[18F]-fluoro-2-deoxy-D-glucose (18F-FDG) uptake on positron emission tomography (PET) in various thoracic neoplasms. In total, 392 patients [non-small cell lung cancer (NSCLC) (n=140), malignant pleural mesothelioma (MPM) (n=21), pulmonary metastatic tumors (PMT) (n=148), thymic epithelial tumors (n=49) and pulmonary neuroendocrine (NE) tumor (n=34)] who underwent 18F-FDG PET before treatment were included in this study. Tumor sections were stained using immunohistochemistry for determination of TS, orotate phosphoribosyltransferase (OPRT), dihydropyrimidine dehydrogenase (DPD), vascular endothelial growth factor (VEGF), microvessel density (MVD), CD34 and p53. The expression of TS in thoracic neoplasms had a positivity of 58% (230/392), and the positive rates of TS expression in NSCLC, PMT, thymic epithelial tumor, NE tumor and MPM samples were 56, 57, 57, 85 and 47%, respectively. The positivity of TS expression was significantly higher in NE tumors compared to that in other thoracic tumors. A statistically significant correlation between TS expression and 18F-FDG uptake was observed in thoracic neoplasms, in particular primary lung adenocarcinomas, high-grade NE tumors, thymomas and MPMs. Moreover, TS expression was closely associated with angiogenesis, DPD, OPRT and p53. Our results indicated that SUVmax by 18F-FDG uptake may be an alternative biomarker for predicting TS expression in patients with primary lung adenocarcinoma, high-grade NE tumor, thymoma and MPM.

View Figures

View References

1	Brundage MD, Davies D and Mackillop WJ: Prognostic factors in non-small cell lung cancer: a decade of progress. Chest. 122:1037–1057. 2002. View Article : Google Scholar : PubMed/NCBI
2	Danenberg PV: Thymidylate synthase - a target enzyme in cancer chemotherapy. Biochim Biophys Acta. 473:73–92. 1977.
3	Wada H, Hitomi S and Teramatsu T: Adjuvant chemotherapy after complete resection in non-small cell lung cancer. West Japan Study Group for Lung Cancer Surgery. J Clin Oncol. 14:1048–1054. 1996.
4	Nakano J, Huang C, Liu D, et al: Evaluation of biomarkers associated with 5-FU sensitivity for non-small-cell lung cancer patients postoperatively treated with UFT. Br J Cancer. 95:607–615. 2006. View Article : Google Scholar : PubMed/NCBI
5	Nakagawa T, Otake Y, Yanagihara K, et al: Expression of thymidylate synthase is correlated with proliferative activity in non-small cell lung cancer (NSCLC). Lung Cancer. 43:145–149. 2004. View Article : Google Scholar : PubMed/NCBI
6	Kaira K, Ohde Y, Nakagawa K, et al: Thymidylate synthase expression is closely associated with outcome in patients with pulmonary adenocarcinoma. Med Oncol. 29:1663–1672. 2012. View Article : Google Scholar : PubMed/NCBI
7	Kaira K, Serizawa M, Koh Y, et al: Expression of thymidylate synthase, orotate phosphoribosyltransferase and dihydropyrimidine dehydrogenase in thymic epithelial tumors. Lung Cancer. 74:419–425. 2011. View Article : Google Scholar
8	Takeda M, Okamoto I, Hirabayashi N, et al: Thymidylate synthase and dihydropyrimidine dehydrogenase expression levels are associated with response to S-1 plus carboplatin in advanced non-small cell lung cancer. Lung Cancer. 73:103–109. 2011. View Article : Google Scholar : PubMed/NCBI
9	Sun JM, Han J, Ahn JS, et al: Significance of thymidylate synthase and thyroid transcription factor 1 expression in patients with nonsquamous non-small cell lung cancer treated with pemetrexed-based chemotherapy. J Thorac Oncol. 6:1392–1399. 2011. View Article : Google Scholar : PubMed/NCBI
10	Righi L, Papotti MG, Ceppi P, et al: Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy. J Clin Oncol. 28:1534–1539. 2010. View Article : Google Scholar
11	Zucali PA, Giovannetti E, Destro A, et al: Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin. Clin Cancer Res. 17:2581–2590. 2011. View Article : Google Scholar : PubMed/NCBI
12	Kaira K, Okumura T, Ohde Y, et al: Prognostic significance of thymidylate synthase expression in the adjuvant chemotherapy after resection for pulmonary metastases from colorectal cancer. Anticancer Res. 31:2763–2771. 2011.
13	Shirasaka T, Shimamato Y, Ohshimo H, et al: Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs. 7:548–557. 1996. View Article : Google Scholar : PubMed/NCBI
14	Kawahara M, Furuse K, Segawa Y, et al: Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer. Br J Cancer. 85:939–943. 2011. View Article : Google Scholar : PubMed/NCBI
15	Shih C, Chen VJ, Gossett LS, et al: LY231514, a pyrrolo[2,3-d] pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res. 57:1116–1123. 1997.
16	Giovannetti E, Backus HH, Wouters D, et al: Changes in the status of p53 affect drug sensitivity to thymidylate synthase (TS) inhibitors by altering TS levels. Br J Cancer. 96:769–775. 2007. View Article : Google Scholar : PubMed/NCBI
17	Gomez HL, Santillana SL, Vallejos CS, et al: A phase II trial of pemetrexed in advanced breast cancer: clinical response and association with molecular target expression. Clin Cancer Res. 12:832–838. 2006. View Article : Google Scholar : PubMed/NCBI
18	Rose MG, Frarrell MP and Schmitz JC: Thymidylate synthase: a critical target for cancer chemotherapy. Clin Colorectal Cancer. 1:220–229. 2002. View Article : Google Scholar : PubMed/NCBI
19	Sasaki R, Komaki R, Macapinlac H, et al: [¹⁸F]fluorodexyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol. 23:1136–1143. 2005.
20	Higashi K, Ueda Y, Arisaka Y, et al: ¹⁸F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer. J Nucl Med. 43:39–45. 2002.
21	Bernard F, Sterman D, Smith RJ, et al: Prognostic value of FDG PET imaging in malignant pleural mesothelioma. J Nucl Med. 40:1241–1245. 1999.PubMed/NCBI
22	Song YS, Lee WW, Chung JH, et al: Correlation between FDG uptake and glucose transporter type 1 expression in neuroendocrine tumors of the lung. Lung Cancer. 61:54–60. 2008. View Article : Google Scholar : PubMed/NCBI
23	Kaira K, Okumura T, Ohde Y, et al: Correlation between ¹⁸F-FDG uptake on PET and molecular biology in metastatic pulmonary tumors. J Nucl Med. 52:705–711. 2011.PubMed/NCBI
24	Kaira K, Endo M, Abe M, et al: Biologic correlation of 2-[¹⁸F]-fluoro-2-deoxy-D-glucose uptake on positron emission tomography in thymic epithelial tumors. J Clin Oncol. 28:3746–3753. 2010.
25	Atkin GK, Daley FM, Bourne S, et al: The impact of surgically induced ichaemia on protein levels in patients undergoing rectal cancer surgery. Br J Cancer. 95:928–933. 2006. View Article : Google Scholar : PubMed/NCBI
26	Kaira K, Endo M, Shukuya T, et al: ¹⁸F-FDG uptake on PET could be a predictive marker of excision repair cross-complementation group 1 (ERCC1) expression in patients with thoracic neoplasms? Neoplasma. 59:257–263. 2012. View Article : Google Scholar
27	Kaira K, Ohde Y, Endo M, et al: Expression of 4F2hc (CD98) in pulmonary neuroendocrine tumors. Oncol Rep. 26:931–937. 2011.PubMed/NCBI
28	Kaira K, Oriuchi N, Takahashi T, et al: L-type amino acid transporter 1 (LAT1) expression in malignant pleural mesothelioma. Anticancer Res. 31:4075–4082. 2011.PubMed/NCBI
29	Ceppi P, Volante M, Saviozzi S, et al: Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer. 107:1589–1596. 2006. View Article : Google Scholar : PubMed/NCBI
30	Hashimoto H, Ozeki Y, Sato M, et al: Significance of thymidylate synthase gene expression level in patients with adenocarcinoma of the lung. Cancer. 106:1595–1601. 2006. View Article : Google Scholar : PubMed/NCBI
31	Ibe T, Shimizu K, Nakano T, et al: High-grade neuroendocrine carcinoma of the lung shows increased thymidylate synthase expression compared to other histotypes. J Surg Oncol. 102:11–17. 2010. View Article : Google Scholar